2026-08-252026-08-25https://scholars.csmu.edu.tw/handle/123456789/16948In recent years, retigabine (KCNQ activator) derivative drugs being developed for the treatment of epilepsy, migraine and neuropathic pain. It activates KCNQ K+ channels by inducing a large hyperp...(詳)近年來retigabine (KCNQ活化劑)的衍生藥物被開發用來治療癲癇、偏頭痛和神經性疼痛。KCNQ活化劑主要是介由KCNQ鉀離子通道恆態活化曲線過極化的偏移而達到穩定神經細胞膜的作用。為...(詳)ML-213KCNQ 活化劑突變蛋白HEK293t分子決定位。ML-213KCNQ activatormutationsHEK293tmolecular determinants.research project